Your browser doesn't support javascript.
loading
ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours.
Segelov, Eva; Waring, Paul; Desai, Jayesh; Wilson, Kate; Gebski, Val; Thavaneswaran, Subotheni; Elez, Elena; Underhill, Craig; Pavlakis, Nick; Chantrill, Lorraine; Nott, Louise; Jefford, Michael; Khasraw, Mustafa; Day, Fiona; Wasan, Harpreet; Ciardiello, Fortunato; Karapetis, Chris; Joubert, Warren; van Hazel, Guy; Haydon, Andrew; Price, Tim; Tejpar, Sabine; Tebbutt, Niall; Shapiro, Jeremy.
Afiliación
  • Segelov E; St Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia. e.segelov@unsw.edu.au.
  • Waring P; University of Melbourne, Melbourne, Australia.
  • Desai J; Royal Melbourne Hospital, Melbourne, Australia.
  • Wilson K; Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Gebski V; NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.
  • Thavaneswaran S; NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.
  • Elez E; NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.
  • Underhill C; Vall d'Hebron University Hospital, Barcelona, Spain.
  • Pavlakis N; Border Medical Oncology, Albury-Wodonga, Australia.
  • Chantrill L; Northern Cancer Institute, Royal North Shore Hospital, University of Sydney, Sydney, Australia.
  • Nott L; Macarthur Cancer Therapy Centre, Campbelltown Hospital, Sydney, Australia.
  • Jefford M; Kinghorn Cancer Centre, Sydney, Australia.
  • Khasraw M; Royal Hobart Hospital, Hobart, Australia.
  • Day F; Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Wasan H; NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.
  • Ciardiello F; Andrew Love Cancer Centre, Geelong, Australia.
  • Karapetis C; Calvary Mater Newcastle, University of Newcastle, Newcastle, Australia.
  • Joubert W; Hammersmith Hospital, London, UK.
  • van Hazel G; Oncologia Medica, Seconda Università degli Studi di Napoli, Naples, Italy.
  • Haydon A; Flinders Medical Centre, Adelaide, Australia.
  • Price T; Princess Alexandra Hospital, Brisbane, Australia.
  • Tejpar S; Sir Charles Gairdner Hospital, Perth, Australia.
  • Tebbutt N; Alfred Hospital, Melbourne, Australia.
  • Shapiro J; Queen Elizabeth Hospital, Lyell McEwin Hospital, Adelaide, Australia.
BMC Cancer ; 16: 339, 2016 05 31.
Article en En | MEDLINE | ID: mdl-27246726
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Proyectos de Investigación / Camptotecina / Neoplasias Colorrectales / Cetuximab / Antineoplásicos Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2016 Tipo del documento: Article País de afiliación: Australia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Proyectos de Investigación / Camptotecina / Neoplasias Colorrectales / Cetuximab / Antineoplásicos Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2016 Tipo del documento: Article País de afiliación: Australia